Gilead Sciences, Inc. (NASDAQ:GILD) is considered one of the most undervalued blue chip stocks to buy now. Analysts at UBS and Citi are bullish on GILEAD, with price target upgrades and ‘Buy’ ratings. Gild exercises option to exclusively license Assembly Biosciences’ long-acting HSV helicase-primase inhibitor programs. Gilead focuses on developing innovative medicines across various medical conditions.

Read more at Yahoo Finance: UBS and Citi Go Bullish on Gilead Sciences (GILD)